文本

中度可信度描述已自动生成

**Supplementary Fig. S1** Flowchart of this study

图表

描述已自动生成

**Supplementary Fig. S2** ROC curve of the Lasso model (Coefficient 1 was obtained at the minimum MSE, and coefficient 2 was obtained at 1 SE MSE. Cutoff values were obtained based on the Youden index)

图表, 条形图

描述已自动生成

**Supplementary Fig. S3** GO enrichment analysis between PECMS groups

图示, 示意图

描述已自动生成

**Supplementary Fig. S4** Level of angiogenesis marker genes and pathway GSVA scores between PECMS groups (ns: no significant difference; \*: P<0.05; \*\*: P<0.005; \*\*\*: P<0.0005; \*\*\*\*: P<0.00005)

图片包含 图示

描述已自动生成

**Supplementary Fig. S5** CIBERSORT score value of different infiltrating immune cells between PECMS groups

表格

描述已自动生成

**Supplementary Fig. S6** Predictive value of molecular targeted drugs between PECMS groups (ns: no significant difference; \*: P<0.05; \*\*: P<0.005; \*\*\*: P<0.0005; \*\*\*\*: P<0.00005)

图示

描述已自动生成

**Supplementary Fig. S7** Survival curve of TCGA-PAAD. The patients were divided by the median value of PECMS feature gene mRNA levels

图片包含 游戏机, 窗户

描述已自动生成

**Supplementary Fig. S8** IHC of PD-L1, CD8, CD31, and SLC2A1 in our single-center retrospective cohort (The patients were grouped by the level of KLHL32)